| Name | Title | Contact Details |
|---|
DNA2.0 is a privately-held, leading synthetic genomics company, headquartered in Menlo Park, CA.
Nivalis Therapeutics (formerly N30Pharma) is developing a novel class of disease modifying therapies that preserve intracellular GSNO (S-nitrosoglutathione), a key regulator of organ repair, regeneration, and healing. The Company’s lead program is focused on cystic fibrosis. As the body’s primary reservoir of nitric oxide (NO), GSNO plays a pivotal role in NO signaling. Decreased GSNO levels are associated with inflammatory lung disease, and with increased activity of GSNOR (GSNO reductase), the primary catabolizing enzyme of GSNO. Nivalis Therapeutics has developed a broad portfolio of proprietary, potent, small molecule inhibitors of GSNOR that have been shown to preserve endogenous GSNO levels and to be effective in “gold-standard” models of inflammatory lung disease. Nivalis Therapeutics is located in Boulder, Colorado.
Tympany, LLC is a Spring, TX-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
To the scientific community, the name Harlan has meant high quality animals for over 70 years. Howard P. Harlan foresaw the need for laboratory animals and founded the business in Indianapolis, Indiana, in 1931. From 1931 until the time of his death in
Rural Wisconsin Health Cooperative is a Sauk City, WI-based company in the Healthcare, Pharmaceuticals, and Biotech sector.